302 related articles for article (PubMed ID: 15343134)
1. Magnetic resonance with manganese-DPDP (mangafodipir) of focal solid pancreatic lesions.
Zanello A; Nicoletti R; Brambilla P; Boccuni R; Di Carlo V; Staudacher C; Del Maschio A
Radiol Med; 2004 Sep; 108(3):194-207. PubMed ID: 15343134
[TBL] [Abstract][Full Text] [Related]
2. [MR imaging of pancreatic lesions with Mn-DPDP. A histopathologic correlation].
Dobritz M; Fellner FA; Baum U; Nömayr A; Lell M; Klein P; Papadopoulos T; Bautz W
Rofo; 2002 Jul; 174(7):893-7. PubMed ID: 12101481
[TBL] [Abstract][Full Text] [Related]
3. [The clinical value of Mn-DPDP: a new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver].
Vogl TJ; Hamm B; Schnell B; Eibl-Eibesfeldt B; Steiner S; Lissner J
Rofo; 1991 Dec; 155(6):568-74. PubMed ID: 1764599
[TBL] [Abstract][Full Text] [Related]
4. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
5. Role of exocrine cells in pancreatic enhancement using Mn-DPDP-enhanced MR imaging.
Gong J; Xu J; Zhou K; Shen K
Chin Med J (Engl); 2002 Sep; 115(9):1363-6. PubMed ID: 12411113
[TBL] [Abstract][Full Text] [Related]
6. MRI with mangafodipir trisodium in the detection of pancreatic tumours: comparison with helical CT.
Rieber A; Tomczak R; Nüssle K; Klaus H; Brambs HJ
Br J Radiol; 2000 Nov; 73(875):1165-9. PubMed ID: 11144793
[TBL] [Abstract][Full Text] [Related]
7. Mangafodipir trisodium-enhanced MR imaging of pancreatic disease.
Boraschi P; Donati F; Gigoni R; Caramella D; Boggi U; Falaschi F; Bartolozzi C
Eur Radiol; 2006 May; 16(5):988-97. PubMed ID: 16421713
[TBL] [Abstract][Full Text] [Related]
8. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
Rofsky NM; Earls JP
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
[TBL] [Abstract][Full Text] [Related]
9. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].
Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M
Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium.
Mayo-Smith WW; Schima W; Saini S; Slater GJ; McFarland EG
AJR Am J Roentgenol; 1998 Mar; 170(3):649-52. PubMed ID: 9490946
[TBL] [Abstract][Full Text] [Related]
11. MR imaging of pancreatic lesions. Comparison of manganese-DPDP and gadolinium chelate.
Diehl SJ; Lehmann KJ; Gaa J; McGill S; Hoffmann V; Georgi M
Invest Radiol; 1999 Sep; 34(9):589-95. PubMed ID: 10485075
[TBL] [Abstract][Full Text] [Related]
12. Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity.
Bernardino ME; Young SW; Lee JK; Weinreb JC
Radiology; 1992 Apr; 183(1):53-8. PubMed ID: 1549694
[TBL] [Abstract][Full Text] [Related]
13. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
14. [Manganese DPDP as a contrast medium for MR tomography of focal liver lesions. Tolerance and image quality in 20 patients].
Kopp AF; Laniado M; Aicher KP; Grönewäller EF; Claussen CD
Rofo; 1992 Dec; 157(6):539-47. PubMed ID: 1457788
[TBL] [Abstract][Full Text] [Related]
15. Focal liver lesions: MR imaging with Mn-DPDP--initial clinical results in 40 patients.
Hamm B; Vogl TJ; Branding G; Schnell B; Taupitz M; Wolf KJ; Lissner J
Radiology; 1992 Jan; 182(1):167-74. PubMed ID: 1309218
[TBL] [Abstract][Full Text] [Related]
16. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.
Youk JH; Lee JM; Kim CS
AJR Am J Roentgenol; 2004 Oct; 183(4):1049-54. PubMed ID: 15385303
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Peterson MS; Oliver JH; Davis PL; Confer SR; Federle MP
Radiology; 1996 Jul; 200(1):69-77. PubMed ID: 8657947
[TBL] [Abstract][Full Text] [Related]
18. Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience.
Gehl HB; Urhahn R; Bohndorf K; Klever P; Hauptmann S; Lodemann KP; Matern S; Schumpelick V; Günther RW
Radiology; 1993 Mar; 186(3):795-8. PubMed ID: 8430190
[TBL] [Abstract][Full Text] [Related]
19. Secretin-stimulated multi-detector CT versus mangafodipir trisodium-enhanced MR imaging plus MRCP in characterization of non-metastatic solid pancreatic lesions.
Boraschi P; Donati F; Gigoni R; Salemi S; Faggioni L; Del Chiaro M; Boggi U; Bartolozzi C; Falaschi F
Dig Liver Dis; 2009 Nov; 41(11):829-37. PubMed ID: 19303825
[TBL] [Abstract][Full Text] [Related]
20. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT.
Oudkerk M; Torres CG; Song B; König M; Grimm J; Fernandez-Cuadrado J; Op de Beeck B; Marquardt M; van Dijk P; de Groot JC
Radiology; 2002 May; 223(2):517-24. PubMed ID: 11997562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
